CV6 Therapeutics to invest almost £8m in clinical trial for new anti-cancer drug

8th June 2023

The drug development company is dedicated to improving the lives of patients with cancer and inflammatory diseases through the development of innovative therapeutics.  Invest NI has offered support of £3m towards the project through a Grant for Research & Development with CV6 raising another £5m of investment from investors including Qubis, Techstart and Clarendon.

Dr Robert Ladner, CEO of CV6 said: “CV6-168 has the potential to be a widely impactful oncology product, significantly improving outcomes for patients in multiple cancer types. Moving into the first-in-human Phase 1a clinical trial is therefore an important milestone for us.

“Pre-clinical studies show that CV6-168 works alongside standard cancer therapies to activate a unique mechanism of action that induces cancer cell DNA damage and cell death while simultaneously activating the immune system to further enhance its anticancer effect.

“This Phase 1a trial will focus on safety, measuring how the drug is absorbed by the body, identifying optimal dosing levels and gathering initial indications of anti-cancer efficacy.

They will be carrying out further scientific research with Queen’s and initiating the clinical trial with sites in the UK, including the Belfast Health and Social Care Trust through the Belfast Experimental Cancer Medicine Centre, with local patients potentially benefiting from the trial. 

Invest NI’s R&D support is part financed by the European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014–2020.